Ragosa Mark 4

What Happened
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals (KNSA), had multiple derivative and equity award transactions on April 1, 2026. He (i) converted/exercised 5,187 derivative units into Class A ordinary shares, (ii) received awards totaling 54,550 restricted/performance share units (31,150 + 7,800 + 15,600), and (iii) had 2,510 shares withheld/sold to cover tax liabilities for proceeds of $120,806 (sale price reported at $48.13 per share). Several small derivative conversions (1,750; 1,591; 1,846) appear in the filing as conversions/dispositions tied to the overall exercise/settlement activity.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (appears timely; Form 4 due within two business days).
• Tax withholding sale: 2,510 shares disposed at $48.13 for $120,806 (code F = tax withholding).
• Derivative activity: conversion/exercise entries totaling 5,187 shares (code M). Several conversion/disposition line items (1,750; 1,591; 1,846) are listed at $0 (typical for vest/settlement entries).
• Awards received: three grant entries totaling 54,550 RSUs/PSUs (code A) recorded at $0 (derivative awards).
• Shares owned after the transactions: not specified in the provided filing details.
• Footnotes of note:
  • RSUs generally convert 1-for-1 into Class A shares (F1); various RSU grants vest over four years with vesting commencement dates of April 1 in 2023, 2024, 2025, and 2026 (F2, F3, F6–F8).
  • PSUs convert into shares based on performance, up to 200% per unit and vest no later than Jan 30, 2029 (F4–F5).
• Transaction codes: M = exercise/conversion of derivative; A = award/grant; F = tax withholding/sale to satisfy tax obligation.

Context

• This was largely award vesting/conversion activity (not an open-market investment). The 2,510-share disposition was a withholding/sale to pay taxes rather than a voluntary open-market sale (common with RSU/option settlements).
• PSUs are performance-based and may convert into a variable number of shares depending on achievement of pre-set goals; RSU awards typically convert 1-for-1.
• These filings are factual disclosures of compensation-related equity activity and do not by themselves indicate Ragosa’s broader market views.